September 20, 2014 8:04 PM ET

Healthcare Providers and Services

Company Overview of Biodesix, Inc.

Company Overview

Biodesix, Inc., a molecular diagnostic company, develops patient care improvement products for personalized medicine. It offers VeriStrat, a clinically validated serum test for advanced non-small cell lung cancer patients; and Clinical Laboratory Improvement Amendments (CLIA) Laboratory to test clinical samples in a CLIA-accredited setting. The company also offers ProTS, a set of analysis algorithms that enable the use of matrix-assisted, laser desorption ionization mass spectrometry for clinical diagnostics. In addition, it designs and implements biomarker development process. Biodesix, Inc. was founded in 2005 and is headquartered in Boulder, Colorado.

2970 Wilderness Place

Suite 100

Boulder, CO 80301

United States

Founded in 2005

Phone:

303-417-0500

Fax:

303-417-9700

Key Executives for Biodesix, Inc.

Chief Executive Officer and Director
Age: 55
Chief Financial Officer
Chief Technology Officer
Vice President of Legal & Regulatory Affairs
Vice President of Human Resources & Organizational Effectiveness
Age: 61
Compensation as of Fiscal Year 2014.

Biodesix, Inc. Key Developments

Biodesix, Inc. Presents at BIOWEST Conference 2014, Sep-10-2014 09:45 AM

Biodesix, Inc. Presents at BIOWEST Conference 2014, Sep-10-2014 09:45 AM. Venue: Marriot City Center, Denver, Colorado, United States. Speakers: David Brunel, CEO.

Aveo Oncology and Biodesix, Inc. to Co-Develop and Commercialize Ficlatuzumab with Companion Diagnostic for Treatment of NSCLC

Aveo Oncology and Biodesix, Inc. announced that they have entered into a worldwide agreement to develop and commercialize Aveo's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). VeriStrat will be used as the selection assay to identify NSCLC patients most likely to benefit from ficlatuzumab. Under the terms of the agreement, Aveo will conduct a proof of concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using the VeriStrat test. Biodesix will fund up to $15 million of the cost of the study. The companies expect to initiate this clinical study later this year. Any additional development, regulatory and commercial costs for ficlatuzumab beyond the proof of concept study will be shared equally as will any potential profits. Subject to regulatory approval, Aveo will lead worldwide commercialization of ficlatuzumab. Biodesix will be responsible for all development, including FDA engagement activities, sales and marketing costs for VeriStrat, and will retain total revenues for sales of VeriStrat.

Aveo Oncology and Biodesix, Inc. Enters into Worldwide Agreement to Co-Develop and Commercialize Ficlatuzumab with Companion Diagnostic for Treatment of NSCLC

Aveo Oncology and Biodesix, Inc. announced that they have entered into a worldwide agreement to develop and commercialize Aveo's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix companion diagnostic test. According to a release, this agreement and the clinical development program will leverage VeriStrat, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). VeriStrat will be used as the selection assay to identify NSCLC patients most likely to benefit from ficlatuzumab. The company noted that an exploratory analysis from Aveo's Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints. Additionally, under the terms of the agreement, Aveo will conduct a proof of concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using the VeriStrat test. Biodesix will fund up to $15 million of the cost of the study. The companies expect to initiate this clinical study later this year. Any additional development, regulatory and commercial costs for ficlatuzumab beyond the proof of concept study will be shared equally as will any potential profits. Subject to regulatory approval, Aveo will lead worldwide commercialization of ficlatuzumab. Biodesix will be responsible for all development, including FDA engagement activities, sales and marketing costs for VeriStrat, and will retain total revenues for sales of VeriStrat.

Similar Private Companies By Industry

Company Name Region
Palestine Principal Healthcare Limited Partnership United States
St Margaret Mercy Healthcare Centers Inc. United States
Concordia of Monroeville United States
US Lifeline Inc United States
WholeHealthMD.com, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 21, 2013
--
Private Placement
October 8, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biodesix, Inc., please visit www.biodesix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.